



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent
Licensee of the Blue Cross and Blue Shield Association

Medical Policy

High-Sensitivity C-Reactive Protein

Table of Contents

- [Policy: Commercial](#)
- [Coding Information](#)
- [Information Pertaining to All Policies](#)
- [Policy: Medicare](#)
- [Description](#)
- [References](#)
- [Authorization Information](#)
- [Policy History](#)
- [Endnotes](#)

Policy Number: 032

BCBSA Reference Number: N/A

NCD/LCD: N/A

Related Policies

None

Policy¹

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Measurement of high sensitivity C-reactive protein (hsCRP) for assessment of coronary artery disease risk may be **MEDICALLY NECESSARY** in individuals who meet all the following criteria:

- The individuals must have undergone previous traditional risk assessment* and been found to have a 10-year risk of cardiovascular heart disease (CHD) between 10-20% (intermediate risk), **AND**
- The test is performed in individuals considered to be metabolically stable and without obvious inflammatory or infectious conditions, **AND**
- When the test is performed twice in a twelve-month period.

* Traditional cardiac risk assessment should consider: Individual gender, age, total cholesterol, HDL cholesterol, systolic blood pressure, smoking status, and personal and family medical history.

Measurement of high sensitivity C-reactive protein (hsCRP) for assessment of coronary artery disease risk is considered **NOT MEDICALLY NECESSARY** in all other situations including, but not limited to:

- Individuals already identified as high risk, **OR**
- Individuals with established coronary artery disease, **OR**
- Serial testing to monitor therapy; **OR**
- Screening asymptomatic individuals among the general population.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is not required .
Commercial PPO and Indemnity	Prior authorization is not required .
Medicare HMO BlueSM	Prior authorization is not required .
Medicare PPO BlueSM	Prior authorization is not required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above **medical necessity criteria MUST** be met for the following codes to be covered for **Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

CPT Codes

CPT codes:	Code Description
86141	C-reactive protein; high sensitivity (hsCRP)

The following **ICD Diagnosis Codes** are considered medically necessary when submitted with the CPT code above if **medical necessity criteria** are met:

ICD-10 Diagnosis Codes

ICD-10-CM-codes:	Code Description
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma
E10.21	Type 1 diabetes mellitus with diabetic nephropathy
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema

E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E10.36	Type 1 diabetes mellitus with diabetic cataract
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene
E10.59	Type 1 diabetes mellitus with other circulatory complications
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy
E10.620	Type 1 diabetes mellitus with diabetic dermatitis
E10.621	Type 1 diabetes mellitus with foot ulcer
E10.622	Type 1 diabetes mellitus with other skin ulcer
E10.628	Type 1 diabetes mellitus with other skin complications
E10.630	Type 1 diabetes mellitus with periodontal disease
E10.638	Type 1 diabetes mellitus with other oral complications
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma
E10.65	Type 1 diabetes mellitus with hyperglycemia
E10.69	Type 1 diabetes mellitus with other specified complication
E10.8	Type 1 diabetes mellitus with unspecified complications
E10.9	Type 1 diabetes mellitus without complications
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma
E11.21	Type 2 diabetes mellitus with diabetic nephropathy
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema

E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E11.36	Type 2 diabetes mellitus with diabetic cataract
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene
E11.59	Type 2 diabetes mellitus with other circulatory complications
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy
E11.620	Type 2 diabetes mellitus with diabetic dermatitis
E11.621	Type 2 diabetes mellitus with foot ulcer
E11.622	Type 2 diabetes mellitus with other skin ulcer
E11.628	Type 2 diabetes mellitus with other skin complications
E11.630	Type 2 diabetes mellitus with periodontal disease
E11.638	Type 2 diabetes mellitus with other oral complications
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma
E11.65	Type 2 diabetes mellitus with hyperglycemia
E11.69	Type 2 diabetes mellitus with other specified complication
E11.8	Type 2 diabetes mellitus with unspecified complications
E11.9	Type 2 diabetes mellitus without complications
E78.0	Pure hypercholesterolemia
E78.1	Pure hyperglyceridemia
E78.2	Mixed hyperlipidemia
E78.5	Hyperlipidemia, unspecified
F17.210	Nicotine dependence, cigarettes, uncomplicated
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders
I10	Essential (primary) hypertension
R03.0	Elevated blood-pressure reading, without diagnosis of hypertension

Description

C-reactive protein (CRP) is an acute phase reactant produced by the liver that has long been used to monitor inflammatory processes, such as infection and autoimmune diseases. Recent studies have suggested that low-level chronic inflammation may play a role in atherogenesis, and thus measurement of CRP has been investigated in various settings of cardiovascular disease, i.e., in patients with known

cardiovascular disease, in patients with risk factors for cardiovascular disease, and as a general risk assessment tool for cardiovascular disease. To be used as a risk assessment tool, a greater precision at lower levels of CRP is needed such that the range of values collected in epidemiologic studies can be subdivided into quartiles and quintiles; in this way, the data from large epidemiologic studies can be applied to individual patients. Such technologies are collectively known as high sensitivity C-reactive protein (hsCRP).

An example of high-sensitivity C-reactive protein testing for assessment of coronary artery disease risk includes the ELISA test. All measurements of high-sensitivity C-reactive protein for assessment of coronary artery disease risk are considered investigational regardless of the commercial name, the manufacturer or FDA approval status except as noted in the policy statement.

Summary

The existing observational evidence establishes that CRP is an independent predictor of cardiovascular disease across a wide spectrum of patient populations. The evidence also suggests that using CRP as a component of a risk assessment tool will result in a more accurate cardiac risk prediction. While there is no scientific literature that directly tests the hypothesis that measurement of C-reactive protein to assess CHD risk results in improved patient outcomes, following discussion with local practitioners and a review of the existing literature, BCBSMA has determined that measurement of high sensitivity C-reactive protein (hsCRP) for assessment of coronary artery disease risk in the patients described in the policy statement is medically necessary.

Policy History

Date	Action
4/2022	Annual policy review. Policy updated with literature review through April 2022. References added. Policy statements unchanged.
5/2020	Annual policy review. Policy updated with literature review through April 2020. References added. Policy statements unchanged.
2/2016	Clarified coding language.
8/2015	Added coding language.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
4/2011	Reviewed - Medical Policy Group – Cardiology and Pulmonology. No changes to policy statements.
4/2010	Reviewed - Medical Policy Group – Cardiology. No changes to policy statements.
4/2009	Reviewed - Medical Policy Group – Cardiology. No changes to policy statements.
4/2008	Reviewed - Medical Policy Group – Cardiology. No changes to policy statements.
4/2007	Reviewed - Medical Policy Group – Cardiology. No changes to policy statements.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45(12):2136-41.
2. Roberts WL, Sedrick R, Moulton L et al. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2000; 46(4):461-8.

3. Ockene IS, Matthews CE, Rifai N et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. *Clin Chem* 2001; 47(3):444-50.
4. Kuller LH, Tracy RP, Shaten J et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. *Multiple Risk Factor Intervention Trial. Am J Epidemiol* 1996; 144(6):537-47.
5. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 1997; 336(14):973-9.
6. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. *Circulation* 1998; 97(20):2007-11.
7. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* 2000; 342(12):836-43.
8. Garcia-Moll X, Zouridakis E, Cole D et al. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. *Eur Heart J* 2000; 21(19):1598-606.
9. Versaci F, Gaspardone A, Tomai F et al. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. *Am J Cardiol* 2000; 85(1):92-5, A8.
10. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Special Report: High-sensitivity C-reactive protein measurement for coronary heart disease risk stratification. *TEC Assessments* 2002; Volume 17, Tab 23.
11. Cao JJ, Arnold AM, Manolio TA et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. *Circulation* 2007; 116(1):32-8.
12. Olsen MH, Hansen TW, Christensen MK et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. *Eur Heart J* 2007; 28(11):1374-81.
13. Ridker PM, Rifai N, Cook NR et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. *JAMA* 2005; 294(3):326-33.
14. Wang TJ, Gona P, Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med* 2006; 355(25):2631-9.
15. Ridker PM, Buring JE, Rifai N et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA* 2007; 297(6):611-9.
16. Zakai NA, Katz R, Jenny NS et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. *J Thromb Haemost* 2007; 5(6):1128-35.
17. Kozan O, Buyukozturk K, Ilerigelen B et al. The impact of plasma high-sensitivity C-reactive protein levels on cardiovascular risk stratification of hypertensive patients: results of the ICEBERG study. *J Clin Hypertens (Greenwich)* 2007; 9(7):500-5.
18. Arruda-Olson AM, Enriquez-Sarano M, Bursi F et al. Left ventricular function and C-reactive protein levels in acute myocardial infarction. *Am J Cardiol* 2010; 105(7):917-21.
19. Park DW, Yun SC, Lee JY et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. *Circulation* 2009; 120(20):1987-95.
20. Perry TE, Muehlschlegel JD, Liu KY et al. Preoperative C-reactive protein predicts long-term mortality and hospital length of stay after primary, nonemergent coronary artery bypass grafting. *Anesthesiology* 2010; 112(3):607-13.
21. Padayachee L, Rodseth RN, Biccard BM. A meta-analysis of the utility of C-reactive protein in predicting early, intermediate-term and long term mortality and major adverse cardiac events in vascular surgical patients. *Anaesthesia* 2009; 64(4):416-24.
22. Chei CL, Yamagishi K, Kitamura A et al. C-reactive protein levels and risk of stroke and its subtype in Japanese: The Circulatory Risk in Communities Study (CIRCS). *Atherosclerosis* 2011; 217(1):187-93.
23. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. *Circulation* 2001; 103(9):1191-3.

24. Ballantyne CM, Hourii J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. *Circulation* 2003; 107(19):2409-15.
25. Hognestad A, Aukrust P, Wergeland R et al. Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. *Clin Cardiol* 2004; 27(4):199-203.
26. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. *J Am Coll Cardiol* 2004; 43(6):1056-61.
27. Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. *N Engl J Med* 2005; 352(1):29-38.
28. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med* 2005; 352(1):20-8.
29. Sattar N, Murray HM, McConnachie A et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). *Circulation* 2007; 115(8):981-9.
30. McMurray JJ, Kjekshus J, Gullestad L et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. *Circulation* 2009; 120(22):2188-96.
31. Emberson J, Bennett D, Link R et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. *Lancet* 2011; 377(9764):469-76.
32. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008; 359(21):2195-207.
33. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; 106(25):3143-421.
34. Abd TT, Eapen DJ, Bajpai A et al. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. *Curr Atheroscler Rep* 2011; 13(2):154-61.
35. Yang EY, Nambi V, Tang Z et al. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. *J Am Coll Cardiol* 2009; 54(25):2388-95.
36. Lim LS, Haq N, Mahmood S et al. Atherosclerotic cardiovascular disease screening in adults: American College Of Preventive Medicine position statement on preventive practice. *Am J Prev Med* 2011; 40(3):381 e1-10.
37. Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2010; 56(25):e50-103.
38. AAFP. Summary of Recommendations for Clinical Preventive Services. 2011. Available online at: http://www.aafp.org/online/etc/medialib/aafp_org/documents/clinical/CPS/rcps08-2005.Par.0001.File.tmp/June2010.pdf. Last accessed July 2011.
39. Buckley DI, Fu R, Freeman M et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. *Ann Intern Med* 2009; 151(7):483-95.
40. Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. *J Am Coll Cardiol* 2008; 51(15):1512-24.
41. Hideki Wada, Tomotaka Dohi, Katsumi Miyauchi, Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention. *Circ J*. 2016 Dec 22;81(1):90-95.
42. Kenji Sakata, Tadatsugu Gamou, Hayato Tada. Low Baseline High-Sensitive C-Reactive Protein Is Associated with Coronary Atherosclerosis Regression: Insights from the MILLION Study. *J Atheroscler Thromb* 2019 May 1;26(5):442-451.
43. Xiaoyu Tang, Ling Mao, Jin Chen et al. High-sensitivity CRP may be a marker of HDL dysfunction and remodeling in patients with acute coronary syndrome. *Sci Rep* 2021 Jun 1;11(1):11444.

Endnotes

¹ Based on local expert opinion